Good results of milder form of ovarian stimulation in an in vitro fertilization/intracytoplasmic sperm injection program

• Published in: Gynecological endocrinology 1999, Vol.13 (5), p.297-304
• Main Authors: Grochowski, D., Wo czy ski, S., Kuczy iski, W., Domitrz, J., Szamatowicz, J., Szamatowicz, M.
• Format: Article
• Language: English
• Subjects: Adult; Clomiphene - administration & dosage; Clomiphene - pharmacology; Clomiphene Citrate; Embryo Transfer; Estradiol - blood; Female; Fertility Agents, Female - administration & dosage; Fertility Agents, Female - pharmacology; Fertilization in Vitro; GNRH Agonist; Humans; In Vitro Fertilization; Intracytoplasmic Sperm Injection; Luteolytic Agents - administration & dosage; Luteolytic Agents - pharmacology; Male; Menotropins - administration & dosage; Menotropins - pharmacology; Ovary - physiology; Ovulation Induction - methods; Pregnancy Rate; Prospective Studies; Prospective Study; Sperm Injections, Intracytoplasmic; Triptorelin Pamoate - administration & dosage; Triptorelin Pamoate - pharmacology
• ISSN: 0951-3590; 1473-0766
• DOI: 10.3109/09513599909167571

In a prospective study, we compared two protocols of ovulation stimulation, the clomiphene citrate and human menopausal gonadotropin (hMG) versus D-triptorelin, a long-acting gonadotropin-releasing hormone (GnRH) agonist and hMG in 324 couples having their first in vitro fertilization or intracytoplasmic sperm injection (IVF/ICSI) program, in terms of pregnancy rates and cost-effectiveness of drugs used. The GnRH agonist/hMG group was characterized by a greater mean number of ampoules of hMG used (31.7 versus 10.2), a larger number of oocytes collected (10.4 versus 4.2), and a larger number of embryos obtained (5.8 versus 2.9). With the policy of transferring only two of the best quality embryos, the mean number of embryos replaced were comparable (1.8 in clomiphene citrate/hMG and 1.9 in GnRH agonist/hMG group). The percentage of patients reaching embryo transfer was lower in the clomiphene citrate/hMG than in the GnRH agonist/hMG group (84.1% versus 93.1%, respectively). However, the combined results of the IVF and ICSI procedure in terms of pregnancy rate, both per patient and per embryo transfer were better, though not significantly in the clomiphene citrate/hMG than in GnRH agonist/hMG group (25.0% and 29.7% versus 23.7% and 25.5%, respectively). Similarly, the implantation rate was better (19.0% versus 13.5%, respectively). With the use of clomiphene citrate/hMG, a fivefold less costly drug regimen, we obtained pregnancy rates equivalent to those gained using GnRH agonist/hMG in our IVF/ICSI program.